Cargando…
DNA Deamination Is Required for Human APOBEC3A-Driven Hepatocellular Carcinoma In Vivo
Although the APOBEC3 family of single-stranded DNA cytosine deaminases is well-known for its antiviral factors, these enzymes are rapidly gaining attention as prominent sources of mutation in cancer. APOBEC3′s signature single-base substitutions, C-to-T and C-to-G in TCA and TCT motifs, are evident...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253583/ https://www.ncbi.nlm.nih.gov/pubmed/37298259 http://dx.doi.org/10.3390/ijms24119305 |
_version_ | 1785056440631689216 |
---|---|
author | Naumann, Jordan A. Argyris, Prokopios P. Carpenter, Michael A. Gupta, Harshita B. Chen, Yanjun Temiz, Nuri A. Zhou, Yufan Durfee, Cameron Proehl, Joshua Koniar, Brenda L. Conticello, Silvestro G. Largaespada, David A. Brown, William L. Aihara, Hideki Vogel, Rachel I. Harris, Reuben S. |
author_facet | Naumann, Jordan A. Argyris, Prokopios P. Carpenter, Michael A. Gupta, Harshita B. Chen, Yanjun Temiz, Nuri A. Zhou, Yufan Durfee, Cameron Proehl, Joshua Koniar, Brenda L. Conticello, Silvestro G. Largaespada, David A. Brown, William L. Aihara, Hideki Vogel, Rachel I. Harris, Reuben S. |
author_sort | Naumann, Jordan A. |
collection | PubMed |
description | Although the APOBEC3 family of single-stranded DNA cytosine deaminases is well-known for its antiviral factors, these enzymes are rapidly gaining attention as prominent sources of mutation in cancer. APOBEC3′s signature single-base substitutions, C-to-T and C-to-G in TCA and TCT motifs, are evident in over 70% of human malignancies and dominate the mutational landscape of numerous individual tumors. Recent murine studies have established cause-and-effect relationships, with both human APOBEC3A and APOBEC3B proving capable of promoting tumor formation in vivo. Here, we investigate the molecular mechanism of APOBEC3A-driven tumor development using the murine Fah liver complementation and regeneration system. First, we show that APOBEC3A alone is capable of driving tumor development (without Tp53 knockdown as utilized in prior studies). Second, we show that the catalytic glutamic acid residue of APOBEC3A (E72) is required for tumor formation. Third, we show that an APOBEC3A separation-of-function mutant with compromised DNA deamination activity and wildtype RNA-editing activity is defective in promoting tumor formation. Collectively, these results demonstrate that APOBEC3A is a “master driver” that fuels tumor formation through a DNA deamination-dependent mechanism. |
format | Online Article Text |
id | pubmed-10253583 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102535832023-06-10 DNA Deamination Is Required for Human APOBEC3A-Driven Hepatocellular Carcinoma In Vivo Naumann, Jordan A. Argyris, Prokopios P. Carpenter, Michael A. Gupta, Harshita B. Chen, Yanjun Temiz, Nuri A. Zhou, Yufan Durfee, Cameron Proehl, Joshua Koniar, Brenda L. Conticello, Silvestro G. Largaespada, David A. Brown, William L. Aihara, Hideki Vogel, Rachel I. Harris, Reuben S. Int J Mol Sci Article Although the APOBEC3 family of single-stranded DNA cytosine deaminases is well-known for its antiviral factors, these enzymes are rapidly gaining attention as prominent sources of mutation in cancer. APOBEC3′s signature single-base substitutions, C-to-T and C-to-G in TCA and TCT motifs, are evident in over 70% of human malignancies and dominate the mutational landscape of numerous individual tumors. Recent murine studies have established cause-and-effect relationships, with both human APOBEC3A and APOBEC3B proving capable of promoting tumor formation in vivo. Here, we investigate the molecular mechanism of APOBEC3A-driven tumor development using the murine Fah liver complementation and regeneration system. First, we show that APOBEC3A alone is capable of driving tumor development (without Tp53 knockdown as utilized in prior studies). Second, we show that the catalytic glutamic acid residue of APOBEC3A (E72) is required for tumor formation. Third, we show that an APOBEC3A separation-of-function mutant with compromised DNA deamination activity and wildtype RNA-editing activity is defective in promoting tumor formation. Collectively, these results demonstrate that APOBEC3A is a “master driver” that fuels tumor formation through a DNA deamination-dependent mechanism. MDPI 2023-05-26 /pmc/articles/PMC10253583/ /pubmed/37298259 http://dx.doi.org/10.3390/ijms24119305 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Naumann, Jordan A. Argyris, Prokopios P. Carpenter, Michael A. Gupta, Harshita B. Chen, Yanjun Temiz, Nuri A. Zhou, Yufan Durfee, Cameron Proehl, Joshua Koniar, Brenda L. Conticello, Silvestro G. Largaespada, David A. Brown, William L. Aihara, Hideki Vogel, Rachel I. Harris, Reuben S. DNA Deamination Is Required for Human APOBEC3A-Driven Hepatocellular Carcinoma In Vivo |
title | DNA Deamination Is Required for Human APOBEC3A-Driven Hepatocellular Carcinoma In Vivo |
title_full | DNA Deamination Is Required for Human APOBEC3A-Driven Hepatocellular Carcinoma In Vivo |
title_fullStr | DNA Deamination Is Required for Human APOBEC3A-Driven Hepatocellular Carcinoma In Vivo |
title_full_unstemmed | DNA Deamination Is Required for Human APOBEC3A-Driven Hepatocellular Carcinoma In Vivo |
title_short | DNA Deamination Is Required for Human APOBEC3A-Driven Hepatocellular Carcinoma In Vivo |
title_sort | dna deamination is required for human apobec3a-driven hepatocellular carcinoma in vivo |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253583/ https://www.ncbi.nlm.nih.gov/pubmed/37298259 http://dx.doi.org/10.3390/ijms24119305 |
work_keys_str_mv | AT naumannjordana dnadeaminationisrequiredforhumanapobec3adrivenhepatocellularcarcinomainvivo AT argyrisprokopiosp dnadeaminationisrequiredforhumanapobec3adrivenhepatocellularcarcinomainvivo AT carpentermichaela dnadeaminationisrequiredforhumanapobec3adrivenhepatocellularcarcinomainvivo AT guptaharshitab dnadeaminationisrequiredforhumanapobec3adrivenhepatocellularcarcinomainvivo AT chenyanjun dnadeaminationisrequiredforhumanapobec3adrivenhepatocellularcarcinomainvivo AT temiznuria dnadeaminationisrequiredforhumanapobec3adrivenhepatocellularcarcinomainvivo AT zhouyufan dnadeaminationisrequiredforhumanapobec3adrivenhepatocellularcarcinomainvivo AT durfeecameron dnadeaminationisrequiredforhumanapobec3adrivenhepatocellularcarcinomainvivo AT proehljoshua dnadeaminationisrequiredforhumanapobec3adrivenhepatocellularcarcinomainvivo AT koniarbrendal dnadeaminationisrequiredforhumanapobec3adrivenhepatocellularcarcinomainvivo AT conticellosilvestrog dnadeaminationisrequiredforhumanapobec3adrivenhepatocellularcarcinomainvivo AT largaespadadavida dnadeaminationisrequiredforhumanapobec3adrivenhepatocellularcarcinomainvivo AT brownwilliaml dnadeaminationisrequiredforhumanapobec3adrivenhepatocellularcarcinomainvivo AT aiharahideki dnadeaminationisrequiredforhumanapobec3adrivenhepatocellularcarcinomainvivo AT vogelracheli dnadeaminationisrequiredforhumanapobec3adrivenhepatocellularcarcinomainvivo AT harrisreubens dnadeaminationisrequiredforhumanapobec3adrivenhepatocellularcarcinomainvivo |